HEMISPHERIAN AS
Developing novel small molecule drugs targeting TET2 for aggressive cancers.
Oversigt
- 5
- Medarbejdere
- 269t NOK
- Omsætning
- 2020
- Grundlagt
Nøglebeslutningstagere
Roger Stupp
Chair of the Clinical Advisory Board
Michael Lim
Member of the Clinical Advisory Board
Monika Hegi
Member of the Clinical Advisory Board
Einar O. Vik-Mo
Member of the Clinical Advisory Board
+2 flere kontakter i Funnelfeedr
Beskrivelse
Hemispherian is an innovative preclinical pharmaceutical company dedicated to redefining targeted cancer therapeutics. The core focus is developing a novel class of small molecule drugs that specifically target the TET2 enzyme. These compounds are designed as targeted therapies for particularly aggr...